High-throughput analysis of drug binding interactions for the human cardiac channel, Kv1.5

Biochemical Pharmacology

Volumn 77, Issue 2, 2009, Pages 177-185

  Karczewski, Jerzy ^a   Kiss, Laszlo ^a   Kane, Stefanie A ^a   Koblan, Kenneth S ^a   Lynch, Robert J ^a   Spencer, Robert H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Atrial fibrillation; Phosphine oxide; Rb+ efflux; Site directed mutagenesis; Voltage gated potassium channel

Indexed keywords

4 PHENYL 4 CYCLOHEXANONE; BIPHENYL DERIVATIVE; CORREOLIDE; CYCLOHEXANONE DERIVATIVE; DIPHENYLPHOSPHINE OXIDE; PHOSPHINE OXIDE DERIVATIVE; POTASSIUM CHANNEL KV1.5; RETINOBLASTOMA PROTEIN; TRITERPENOID; UNCLASSIFIED DRUG; VOLTAGE GATED POTASSIUM CHANNEL;

ACCURACY; ANIMAL CELL; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG TARGETING; ELECTROPHYSIOLOGY; GENE MUTATION; HEART ATRIUM ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM MUSCLE; HEART MUSCLE REFRACTORY PERIOD; HEART REPOLARIZATION; HIGH THROUGHPUT SCREENING; MEMBRANE POTENTIAL; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RECEPTOR BINDING; SITE DIRECTED MUTAGENESIS;

ANIMALS; ATRIAL FIBRILLATION; CHO CELLS; CRICETINAE; CRICETULUS; CYCLOHEXANONES; ELAPID VENOMS; ELECTROPHYSIOLOGY; HUMANS; KINETICS; KV1.5 POTASSIUM CHANNEL; MUTAGENESIS, SITE-DIRECTED; MYOCYTES, CARDIAC; PATCH-CLAMP TECHNIQUES; PHOSPHINES; POLYMERASE CHAIN REACTION; RUBIDIUM; SPECTROPHOTOMETRY, ATOMIC; TRITERPENES;

EID: 57249096990     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.09.035     Document Type: Article

References (36)

1. Miller C. An overview of the potassium channel family. Genome Biol 1 (2000) REVIEWS0004
2. Moulton G., Attwood T.K., Parry-Smith D.J., and Packer J.C. Phylogenomic analysis and evolution of the potassium channel gene family. Recept Channels 9 (2003) 363-377
3. Gopalakrishnan M., Char-Chang Shieh C., and Chen J. Potassium channels. In: Mannhold R.K., and Hugo/Folkers G. (Eds). Voltage-gated ion channels as drug targets (2006), Wiley-VCH
4. Gaborit N., Le Bouter S., Szuts V., Varro A., Escande D., Nattel S., et al. Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol 582 (2007) 675-693
5. Wang Z., Fermini B., and Nattel S. Sustained depolarization-induced outward current in human atrial myocytes. Evidence for a novel delayed rectifier K+ current similar to Kv1.5 cloned channel currents. Circ Res 73 (1993) 1061-1076
6. Fedida D., Wible B., Wang Z., Fermini B., Faust F., Nattel S., et al. Identity of a novel delayed rectifier current from human heart with a cloned K+ channel current. Circ Res 73 (1993) 210-216
7. Lagrutta A., Wang J., Fermini B., and Salata J.J. Novel, potent inhibitors of human Kv1.5 K+ channels and ultrarapidly activating delayed rectifier potassium current. J Pharmacol Exp Ther 317 (2006) 1054-1063
8. Stump G.L., Wallace A.A., Regan C.P., and Lynch Jr. J.J. In vivo antiarrhythmic and cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-isopropyl-5-methylcyclohexyl) diphenylphosphine oxide. J Pharmacol Exp Ther 315 (2005) 1362-1367
9. Regan C.P., Wallace A.A., Cresswell H.K., Atkins C.L., and Lynch Jr. J.J. In vivo cardiac electrophysiologic effects of a novel diphenylphosphine oxide IKur blocker (2-Isopropyl-5-methylcyclohexyl) diphenylphosphine oxide, in rat and nonhuman primate. J Pharmacol Exp Ther 316 (2006) 727-732
10. Hu W., Toral J., Cervoni P., Ziai M.R., and Sokol P.T. Depolarization-induced 86Rb+ efflux in CHO cells expressing a recombinant potassium channel. J Pharmacol Toxicol Methods 34 (1995) 1-7
11. Bouchard R., and Fedida D. Closed- and open-state binding of 4-aminopyridine to the cloned human potassium channel Kv1.5. J Pharmacol Exp Ther 275 (1995) 864-876
12. Snyders D.J., Tamkun M.M., and Bennett P.B. A rapidly activating and slowly inactivating potassium channel cloned from human heart. Functional analysis after stable mammalian cell culture expression. J Gen Physiol 101 (1993) 513-543
13. Hurst R.S., Busch A.E., Kavanaugh M.P., Osborne P.B., North R.A., and Adelman J.P. Identification of amino acid residues involved in dendrotoxin block of rat voltage-dependent potassium channels. Mol Pharmacol 40 (1991) 572-576
14. Liang A.H., Santarelli V.P., Bennett P., and Imredy J.P. Effect of neutralization of lysine clusters flanking the binding domain of dendrotoxin on its affinity for a Kv1.5 mutant. Biophys J 82 (2002) 584
15. Zhang H., Zhu B., Yao J.A., and Tseng G.N. Differential effects of S6 mutations on binding of quinidine and 4-aminopyridine to rat isoform of Kv1.4: common site but different factors in determining blockers' binding affinity. J Pharmacol Exp Ther 287 (1998) 332-343
16. Yeola S.W., Rich T.C., Uebele V.N., Tamkun M.M., and Snyders D.J. Molecular analysis of a binding site for quinidine in a human cardiac delayed rectifier K+ channel. Role of S6 in antiarrhythmic drug binding. Circ Res 78 (1996) 1105-1114
17. Fedida D. Gating charge and ionic currents associated with quinidine block of human Kv1.5 delayed rectifier channels. J Physiol 499 Pt 3 (1997) 661-675
18. Grissmer S., Nguyen A.N., Aiyar J., Hanson D.C., Mather R.J., Gutman G.A., et al. Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol 45 (1994) 1227-1234
19. Lin S., Wang Z., and Fedida D. Influence of permeating ions on Kv1.5 channel block by nifedipine. Am J Physiol Heart Circ Physiol 280 (2001) H1160-H1172
20. Caballero R., Moreno I., Gonzalez T., Valenzuela C., Tamargo J., and Delpon E. Putative binding sites for benzocaine on a human cardiac cloned channel (Kv1.5). Cardiovasc Res 56 (2002) 104-117
21. Choi B.H., Choi J.S., Rhie D.J., Yoon S.H., Min D.S., Jo Y.H., et al. Direct inhibition of the cloned Kv1.5 channel by AG-1478, a tyrosine kinase inhibitor. Am J Physiol Cell Physiol 282 (2002) C1461-C1468
22. Peukert S., Brendel J., Pirard B., Bruggemann A., Below P., Kleemann H.W., et al. Identification, synthesis, and activity of novel blockers of the voltage-gated potassium channel Kv1.5. J Med Chem 46 (2003) 486-498
23. Decher N., Pirard B., Bundis F., Peukert S., Baringhaus K.H., Busch A.E., et al. Molecular basis for Kv1.5 channel block: conservation of drug binding sites among voltage-gated K+ channels. J Biol Chem 279 (2004) 394-400
24. Wirth K.J., Paehler T., Rosenstein B., Knobloch K., Maier T., Frenzel J., et al. Atrial effects of the novel K(+)-channel-blocker AVE0118 in anesthetized pigs. Cardiovasc Res 60 (2003) 298-306
25. Gogelein H., Brendel J., Steinmeyer K., Strubing C., Picard N., Rampe D., et al. Effects of the atrial antiarrhythmic drug AVE0118 on cardiac ion channels. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 183-192
26. Decher N., Kumar P., Gonzalez T., Pirard B., and Sanguinetti M.C. Binding site of a novel Kv1.5 blocker: a "foot in the door" against atrial fibrillation. Mol Pharmacol 70 (2006) 1204-1211
27. Naccarelli G.V., Wolbrette D.L., Samii S., Banchs J.E., Penny-Peterson E., Stevenson R., et al. Vernakalant-a promising therapy for conversion of recent-onset atrial fibrillation. Expert Opin Investig Drugs 17 (2008) 805-810
28. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs 16 (2007) 519-532
29. Wirth K.J., Brendel J., Steinmeyer K., Linz D.K., Rutten H., and Gogelein H. In vitro and in vivo effects of the atrial selective antiarrhythmic compound AVE1231. J Cardiovasc Pharmacol 49 (2007) 197-206
30. Eldstrom J., Wang Z., Xu H., Pourrier M., Ezrin A., Gibson K., et al. The molecular basis of high-affinity binding of the antiarrhythmic compound vernakalant (RSD1235) to Kv1.5 channels. Mol Pharmacol 72 (2007) 1522-1534
31. Schmalhofer W.A., Bao J., McManus O.B., Green B., Matyskiela M., Wunderler D., et al. Identification of a new class of inhibitors of the voltage-gated potassium channel, Kv1.3, with immunosuppressant properties. Biochemistry 41 (2002) 7781-7794
32. Hanner M., Schmalhofer W.A., Green B., Bordallo C., Liu J., Slaughter R.S., et al. Binding of correolide to K(v)1 family potassium channels. Mapping the domains of high affinity interaction. J Biol Chem 274 (1999) 25237-25244
33. Thai K.M., and Ecker G.F. A binary QSAR model for classification of hERG potassium channel blockers. Bioorg Med Chem 16 (2008) 4107-4119
34. Thai K.M., and Ecker G.F. Predictive models for HERG channel blockers: ligand-based and structure-based approaches. Curr Med Chem 14 (2007) 3003-3026
35. Beene D.L., Dougherty D.A., and Lester H.A. Unnatural amino acid mutagenesis in mapping ion channel function. Curr Opin Neurobiol 13 (2003) 264-270
36. Remillard C.V., Tigno D.D., Platoshyn O., Burg E.D., Brevnova E.E., Conger D., et al. Function of Kv1.5 channels and genetic variations of KCNA5 in patients with idiopathic pulmonary arterial hypertension. Am J Physiol Cell Physiol 292 (2007) C1837-C1853